This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited.
If you don't agree, please click here.
established from the pleural effusion of a 53-year-old woman with chronic myeloid leukemia (CML) in blast crisis in 1970; cells carry the BCR-ABL1 e14-a2 (b3-a2) fusion gene; this subclone (ACC 10) weakly expresses MHC class I (image); other subclones (ACC 86 and ACC 92) are MHC class I negative and might be used in in-vitro natural killer assays; cells produce hemoglobin. Exome and RNA sequence data are available (see Ref 18187 and
Exome sequence and RNA-Seq)
seed out at ca. 0.5 x 106 cells/ml; maintain at 0.1-1.0 x 106 cells/ml; split 1:3 to 1:5 every 3 days; viability may be low after thawing, but cells recover during the following 2-3 days; starting the culture with 20% FBS in 12- or 24-well-plates could be of advantage
at 37 °C with 5% CO2
ca. 30-40 hours
maximal density at 1.0-1.5 x 106 cells/ml
frozen with 70% medium, 20% FBS, 10% DMSO
DSMZ Scientific Data:
contamination was eliminated with Ciprobay (ciprofloxacin), then negative in DAPI, microbiological culture, PCR assays
STR analysis according to the global standard ANSI/ATCC ASN-0002.1-2021 (2021) resulted in an authentic STR profile of the reference STR database.
human hypotriploid karyotype with sharp mode - 61-68<3n>XX, -X, -3, +7, -13, -18, +3mar, del(9)(p11/13), der(14)t(14;?)(p11;?), der(17)t(17;?)(p11/13;?), der(?18)t(15;?18)(q21;?q12), del(X)(p22) - two markers appear from FISH to have arisen from Ph
expression of fusion gene BCR-ABL1 (e14-a2) confirmed by RT-PCR